Magnetic resonance perfusion image features uncover an angiogenic subgroup of glioblastoma patients with poor survival and better response to antiangiogenic treatment

BACKGROUND. In previous clinical trials, antiangiogenic therapies such as bevacizumab did not show efficacy in patients with newly diagnosed glioblastoma (GBM). This may be a result of the heterogeneity of GBM, which has a variety of imaging-based phenotypes and gene expression patterns. In this stu...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Neuro Oncol
Autores principales: Liu, Tiffany T., Achrol, Achal S., Mitchell, Lex A., Rodriguez, Scott A., Feroze, Abdullah, Iv, Michael, Kim, Christine, Chaudhary, Navjot, Gevaert, Olivier, Stuart, Josh M., Harsh, Griffith R., Chang, Steven D., Rubin, Daniel L.
Formato: Artigo
Lenguaje:Inglês
Publicado: Oxford University Press 2017
Materias:
Basic and Translational Investigations
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5570189/
https://ncbi.nlm.nih.gov/pubmed/28007759
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/now270
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares